APO Research
Talk to an analyst

APO RESEARCH · REPORT

PMO (Phosphorodiamidate Morpholino Oligomers) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Outlook and Growth Opportunities 2026

29 December 2025198 pages

Choose your research edition.

Industry ResearchPMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PMO (Phosphorodiamidate Morpholino Oligomers) Drug market include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PMO (Phosphorodiamidate Morpholino Oligomers) Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market.

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Company

Avidity Biosciences

Dyne

Nippon Shinyaku

NS Pharma, Inc.

Sarepta Therapeutics, Inc

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type

DMD exon 45 Based

DMD exon 51 Based

DMD exon 53 Based

Other

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application

Hospital

Clinic

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the PMO (Phosphorodiamidate Morpholino Oligomers) Drug key companies, revenue, market share, and recent developments.

3. To split the PMO (Phosphorodiamidate Morpholino Oligomers) Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions PMO (Phosphorodiamidate Morpholino Oligomers) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PMO (Phosphorodiamidate Morpholino Oligomers) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze PMO (Phosphorodiamidate Morpholino Oligomers) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug industry.

Chapter 3: Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of PMO (Phosphorodiamidate Morpholino Oligomers) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of PMO (Phosphorodiamidate Morpholino Oligomers) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends Table 2. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers Table 3. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges Table 4. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints Table 5. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Company (2021-2026) Table 7. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Company Manufacturing Base & Headquarters Table 9. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company, Product Type & Application Table 10. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DMD exon 45 Based Table 15. Significant Companies of DMD exon 51 Based Table 16. Significant Companies of DMD exon 53 Based Table 17. Significant Companies of Other Table 18. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type (2021-2026) Table 22. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application (2021-2026) Table 29. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application (2027-2032) Table 30. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Region (2021-2026) Table 33. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Region (2027-2032) Table 35. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Market Share by Country (2021-2026) Table 38. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Market Share by Country (2027-2032) Table 40. Avidity Biosciences Company Information Table 41. Avidity Biosciences Business Overview Table 42. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 44. Avidity Biosciences Recent Development Table 45. Dyne Company Information Table 46. Dyne Business Overview Table 47. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 49. Dyne Recent Development Table 50. Nippon Shinyaku Company Information Table 51. Nippon Shinyaku Business Overview Table 52. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 54. Nippon Shinyaku Recent Development Table 55. NS Pharma, Inc. Company Information Table 56. NS Pharma, Inc. Business Overview Table 57. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 59. NS Pharma, Inc. Recent Development Table 60. Sarepta Therapeutics, Inc Company Information Table 61. Sarepta Therapeutics, Inc Business Overview Table 62. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 64. Sarepta Therapeutics, Inc Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Image Figure 2. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DMD exon 45 Based Image Figure 8. DMD exon 51 Based Image Figure 9. DMD exon 53 Based Image Figure 10. Other Image Figure 11. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application (2021-2032) Figure 19. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • DMD exon 45 Based
  • DMD exon 51 Based
  • DMD exon 53 Based
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Avidity Biosciences
  • Dyne
  • Nippon Shinyaku
  • NS Pharma, Inc.
  • Sarepta Therapeutics, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Dynamics
  1. 2.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
  2. 2.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers
  3. 2.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges
  4. 2.4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints
3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Company
  1. 3.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Revenue Ranking in 2025
  2. 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Company (2021-2026)
  3. 3.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Ranking (2024-2026)
  4. 3.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Product Type and Application
  6. 3.6 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Type
  1. 4.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Type Introduction
  2. 4.1.1 DMD exon 45 Based
  3. 4.1.2 DMD exon 51 Based
  4. 4.1.3 DMD exon 53 Based
  5. 4.1.4 Other
  6. 4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type
  7. 4.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Type (2021-2032)
  9. 4.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type (2021-2032)
5 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Application
  1. 5.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application
  5. 5.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Application (2021-2032)
  7. 5.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application (2021-2032)
6 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Regional Value Analysis
  1. 6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032)
  7. 6.3.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032)
  10. 6.4.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032)
  16. 6.6.2 South America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Country, 2025 VS 2032
7 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Country-level Value Analysis
  1. 7.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Avidity Biosciences
  2. 8.1.1 Avidity Biosciences Company Information
  3. 8.1.2 Avidity Biosciences Business Overview
  4. 8.1.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  6. 8.1.5 Avidity Biosciences Recent Developments
  7. 8.2 Dyne
  8. 8.2.1 Dyne Company Information
  9. 8.2.2 Dyne Business Overview
  10. 8.2.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  12. 8.2.5 Dyne Recent Developments
  13. 8.3 Nippon Shinyaku
  14. 8.3.1 Nippon Shinyaku Company Information
  15. 8.3.2 Nippon Shinyaku Business Overview
  16. 8.3.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  18. 8.3.5 Nippon Shinyaku Recent Developments
  19. 8.4 NS Pharma, Inc.
  20. 8.4.1 NS Pharma, Inc. Company Information
  21. 8.4.2 NS Pharma, Inc. Business Overview
  22. 8.4.3 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  24. 8.4.5 NS Pharma, Inc. Recent Developments
  25. 8.5 Sarepta Therapeutics, Inc
  26. 8.5.1 Sarepta Therapeutics, Inc Company Information
  27. 8.5.2 Sarepta Therapeutics, Inc Business Overview
  28. 8.5.3 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  30. 8.5.5 Sarepta Therapeutics, Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst